Recurrent venous thromboembolism · patients with venous thromboembolism.
10 mg warfarin nomogram showed no clear difference in recurrent venous thromboembolism sonography or lung scan or chest… compared with 5 mg warfarin nomogram (low certainty).
1 finding from 1 review
Major bleeding fall in hemoglobin of > 20 g/L or transfusion of 2 or more units of red cells · patients with venous thromboembolism.
10 mg warfarin nomogram showed no clear difference in major bleeding fall in hemoglobin of > 20 g/L or transfusion of 2 or… compared with 5 mg warfarin nomogram (moderate certainty).
1 finding from 1 review
Minor bleeding · patients with venous thromboembolism.
It is very uncertain whether 10 mg warfarin nomogram changes minor bleeding it is not major bleeding compared with 5 mg warfarin nomogram (very low certainty).
1 finding from 1 review
Duration of hospital stay (days) for 'rescue' therapy · patients with venous thromboembolism.
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · patients with hirsutism
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg showed no clear difference in proportion of participants who reported an adverse event compared with ethinyl estradiol 30 μg + desogestrel 0.15 mg (moderate certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · patients with hirsutism
1 finding from 1 review
Change in serum androgen levels · patients with hirsutism
1 finding from 1 review
Participant‐reported improvement of hirsutism ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants who reported an adverse event · women with hirsutism
It is very uncertain whether flutamide 250 mg once to twice daily changes proportion of participants who reported an adverse event compared with metformin 1275 mg to 1700 mg per day (very low certainty).
1 finding from 1 review
Clinician's assessment of improvement of hirsutism Ferriman‐Gallwey score Scale from: 0 to 36 · women with hirsutism
1 finding from 1 review
Change in serum androgen levels · women with hirsutism
1 finding from 1 review
Change in BMI3 kg/m² · women with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism ‐ not measured · women with hirsutism
1 finding from 1 review
Change in BMI · patients with hirsutism
1 finding from 1 review
Improvement of other clinical signs of hyperandrogenism Acne score ‐ grade 1 to 4 (higher is worse) · patients with hirsutism
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6‐9 mg changes continued remission at 12 months compared with azathioprine 2‐2.5 mg/kg (very low certainty).
1 finding from 1 review
Complete suppression of urticaria: intermediate‐term duration of intervention · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in complete suppression of urticaria: intermediate‐term duration of… compared with desloratadine 5 mg (low certainty).
1 finding from 1 review